Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

761 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.
Stepanishyna Y, Manni M, Civallero M, Shokun N, Skrypets T, Burtna A, Shapovalenko N, Tytorenko I, Aleksyk O, Pastushenko Y, Gubareva H, Moiseienko K, Kadnikova T, Rudyuk T, Filonenko K, Martynchyk A, Novosad O, Galli GR, Kryachok I, Federico M. Stepanishyna Y, et al. Among authors: federico m. Br J Haematol. 2024 May;204(5):1757-1761. doi: 10.1111/bjh.19352. Epub 2024 Feb 23. Br J Haematol. 2024. PMID: 38400556
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.
Fiaccadori V, Neven A, Fortpied C, Aurer I, Andre M, Federico M, Counsell N, Phillips EH, Clifton-Hadley L, Barrington SF, Illidge T, Radford J, Raemaekers JMM. Fiaccadori V, et al. Among authors: federico m. Br J Haematol. 2023 Mar;200(6):731-739. doi: 10.1111/bjh.18594. Epub 2022 Dec 21. Br J Haematol. 2023. PMID: 36541117
A Quality Control Study on Involved Node Radiation Therapy in the European Organisation for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi H10 Trial on Stages I and II Hodgkin Lymphoma: Lessons Learned.
Aleman BMP, Ricardi U, van der Maazen RWM, Meijnders P, Beijert M, Boros A, Izar F, Janus CPM, Levis M, Martin V, Specht L, Corning C, Clementel E, Raemaekers JM, André MP, Federico M, Fortpied C, Girinsky T. Aleman BMP, et al. Among authors: federico m. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):664-674. doi: 10.1016/j.ijrobp.2023.05.011. Epub 2023 May 12. Int J Radiat Oncol Biol Phys. 2023. PMID: 37179034
First Results from a Broadband Search for Dark Photon Dark Matter in the 44 to 52  μeV Range with a Coaxial Dish Antenna.
Knirck S, Hoshino G, Awida MH, Cancelo GI, Di Federico M, Knepper B, Lapuente A, Littmann M, Miller DW, Mitchell DV, Rodriguez D, Ruschman MK, Sawtell MA, Stefanazzi L, Sonnenschein A, Teafoe GW, Bowring D, Carosi G, Chou A, Chang CL, Dona K, Khatiwada R, Kurinsky NA, Liu J, Pena C, Salemi CP, Wang CW, Yu J; BREAD Collaboration. Knirck S, et al. Among authors: di federico m. Phys Rev Lett. 2024 Mar 29;132(13):131004. doi: 10.1103/PhysRevLett.132.131004. Phys Rev Lett. 2024. PMID: 38613261
Reply to T. Vassilakopoulos et al.
Federico M, Plattel W, Hutchings M, Stepanishyna Y, Fortpied C, André M. Federico M, et al. J Clin Oncol. 2024 Apr 9:JCO2400143. doi: 10.1200/JCO.24.00143. Online ahead of print. J Clin Oncol. 2024. PMID: 38593392 No abstract available.
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
Civallero M, Schroers-Martin JG, Horwitz S, Manni M, Stepanishyna Y, Cabrera ME, Vose J, Spina M, Hitz F, Nagler A, Montoto S, Chiattone C, Skrypets T, Perez Saenz MA, Priolo G, Luminari S, Lymboussaki A, Pavlovsky A, Marino D, Liberati M, Trotman J, Mannina D, Federico M, Advani R. Civallero M, et al. Among authors: federico m. Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19433. Online ahead of print. Br J Haematol. 2024. PMID: 38532575
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Among authors: federico m. Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print. Haematologica. 2024. PMID: 38497158 Free article.
761 results